Schaeffler, Andreas (2006) Treatment of pituitary gland hyperfunction. From acromegaly to prolactinoma. INTERNIST, 47 (12). 1215-+. ISSN 0020-9554,
Full text not available from this repository. (Request a copy)Abstract
Evidence based drug therapy is currently available for the treatment of prolactinomas and growth hormone secreting adenomas ( acromegaly). Dopamine agonists such as bromocriptine, quinagolide or cabergoline represent the standard therapy for the treatment of micro- and macro-prolaktinomas. In pregnancy, more differentiated, individual and patient-adapted therapeutic procedures have to be considered. Transsphenoidal adenomectomy is the treatment of choice for patients suffering from acromegaly. If biochemical cure ( defined by normalized IGF-1 serum levels or by a GH nadir < 1 mu g/l during a 3-h oral glucose tolerance test) cannot be achieved, somatostatin analogues such as octreotide and lanreotide are effective. In some cases, dopamine agonists can be added. In therapy-resistant cases, growth hormone receptor antagonists can be used.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | HORMONE-RECEPTOR ANTAGONIST; LONG-TERM; SOMATOSTATIN ANALOGS; FOLLOW-UP; CABERGOLINE; THERAPY; HYPERPROLACTINEMIA; PEGVISOMANT; OCTREOTIDE; ADENOMAS; prolactinoma; acromegaly; pituitary gland; dopamine agonist; somatostatin analogues |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 18 Jan 2021 08:00 |
| Last Modified: | 18 Jan 2021 08:00 |
| URI: | https://pred.uni-regensburg.de/id/eprint/33692 |
Actions (login required)
 |
View Item |
